Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
News|Articles|December 2, 2024
Presenting Our December Theme: Year in Review
Author(s)Leah Kuntz
Listen
0:00 / 0:00
Key Takeaways
- Psychiatric Times invites clinicians to reflect on their year's learnings and share insights with peers, focusing on psychiatric practice advancements.
- Contributions can include opinion pieces, case studies, or CME articles, promoting knowledge exchange among psychiatric professionals.
Do you want to be featured in our online series? Check out our December theme!
Advertisement
This year, Psychiatric Times is featuring monthly themes that speak to various aspects of psychiatry and issues relevant to psychiatric clinicians. Our December theme asks us to look back at this year with a clinical eye: What did you learn this year in your psychiatric practice? What do you want to share with your fellow clinicians? What populations are currently underserved and how can we help?
If you have something you want to share, whether that's an opinion piece, case study example, or CME article, let us know! Write to us now at
Advertisement
Related to this article
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
3
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
4
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5